← Back to Screener
Adial Pharmaceuticals, Inc (ADIL)
Price$2.45
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-83.76%
Price vs S&P 500 (4W)49.87%
VGM Score34.47
Market Capitalization$5.25M
All Metrics
Book Value / Share (Quarterly)$2.46
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.32
Price vs S&P 500 (YTD)-67.30%
EPS (TTM)$-9.93
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-9.93
EPS (Annual)$-11.93
ROI (Annual)-151.18%
Cash / Share (Quarterly)$3.04
ROA (Last FY)-119.54%
EBITD / Share (TTM)$-7.98
ROE (5Y Avg)-308.49%
Cash Flow / Share (Annual)$-5.84
P/B Ratio1.41x
P/B Ratio (Quarterly)0.69x
Net Income / Employee (Annual)$-1,595,400
Net Interest Coverage (TTM)-22.29x
ROA (TTM)-127.59%
EPS Incl Extra (Annual)$-11.93
Current Ratio (Annual)4.42x
Quick Ratio (Quarterly)3.04x
3-Month Avg Trading Volume0.07M
52-Week Price Return-86.05%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.46
52-Week High$440.66
EPS Excl Extra (Annual)$-11.93
Tangible BV CAGR (5Y)5.84%
26-Week Price Return-67.83%
Quick Ratio (Annual)4.21x
13-Week Price Return-5.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.18x
Enterprise Value$667,800
Book Value / Share Growth (5Y)-7.10%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.29
3-Month Return Std Dev107.94%
Net Income / Employee (TTM)$-1,554,200
ROE (Last FY)-151.18%
Net Interest Coverage (Annual)-31.96x
EPS Basic Excl Extra (Annual)$-11.93
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-9.93
ROI (TTM)-162.83%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.75
Price vs S&P 500 (52W)-114.25%
Year-to-Date Return-56.36%
5-Day Price Return15.38%
EPS Normalized (Annual)$-11.93
ROA (5Y Avg)-194.30%
Month-to-Date Return55.84%
Cash Flow / Share (TTM)$-4.58
EBITD / Share (Annual)$-11.66
ROI (5Y Avg)-308.49%
EPS Basic Excl Extra (TTM)$-9.93
P/TBV (Quarterly)0.69x
P/B Ratio (Annual)1.11x
Book Value / Share (Annual)$4.75
Price vs S&P 500 (13W)-14.88%
Beta-698.44x
Revenue / Share (TTM)$0.00
ROE (TTM)-162.83%
52-Week Low$1.31
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.48est. -2.78
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ADILAdial Pharmaceuticals, Inc | — | — | D | $2.45 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing prescription treatments for addiction and related disorders. Its lead candidate, AD04, is an ondansetron-based therapy for alcohol use disorder, designed to address a significant unmet medical need in addiction medicine.